Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14310%2F04%3A00035997" target="_blank" >RIV/00216224:14310/04:00035997 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors

Original language description

The title pyrazolo[1,5-a]pyrimidines [I; Q = SO2NR6R7, CONR6R7, CO2R7; R2 = (un)substituted alkyl, alkynyl, alkynylalkyl, cycloalkyl, CF3, CO2R6, aryl, arylalkyl, heteroarylalkyl, heterocyclyl, etc., wherein aryl is optionally substituted; R3 = H, halogen, NR5R6, CONR5R6, CO2R4, each (un)substituted alkyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, etc.; R4 = H, halo, alkyl; R5 = H, alkyl; R6 = H, each (un)substituted alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; R7 = each (un)substituted alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R5 and R6 in the moiety -NR5R6, may be joined together to form an (un)substitutedcycloalkyl or heterocyclyl] or pharmaceutically acceptable salts or solvates thereof are prepd. In its many embodiments, the present invention also provides methods of prepg. such compds., pharmaceutical compns. contg. one or more such co

Czech name

—

Czech description

—

Type

P - Patent

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2004

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Patent/design ID

WO 2004/022062 A1

Publisher

—

Publisher name

—

Place of publication

—

Publication country

—

Date of acceptance

Mar 18, 2004

Owner name

Schering Plough; Pharmacopeia

Method of use

A - Výsledek využívá pouze poskytovatel

Usage type

A - K využití výsledku jiným subjektem je vždy nutné nabytí licence